Regulatory FDA moves toward easing restrictions on certain peptides BioPharma DiveThe agency s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F.RegulatoryRead full story pharminent April 16, 2026 (Last updated: April 17, 2026) BioPharma Dive The agency s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. RegulatoryRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s new obesity pill passes heart safety test in diabetesNext: Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
